I am a board-certified hematologist and oncologist, and specialize in caring for cancer patients with disorders of the coagulation system. My expertise is in the evaluation and management of bleeding disorders or problems associated with abnormal clotting, and I work closely with the highly skilled surgeons at Memorial Sloan Kettering to ensure that patients with these disorders who need to undergo surgery do so safely without any complications.
Patients with cancer may develop abnormal blood clots. I work closely with the medical oncologists in all specialties to ensure that patients are treated safely and appropriately for blood clots while receiving cancer chemotherapy. Chemotherapy can often lower the blood counts such as white cells, red cells and platelets. I also specialize in the evaluation and treatment of abnormalities in the blood counts to allow patients to proceed with chemotherapy with mimimal side effects related to low counts.
I am currently the chair of the hemostasis study group of the Multinational Association of Supportive Care in Cancer. My research interests include studying the optimal treatment and duration of treatment of cancer associated thrombosis. I enjoy teaching and mentoring the next generation of physicians and was honored to receive the 2010-2011 Hematology Attending Teaching Award, selected by fellows from Memorial Sloan Kettering’s Hematology/Oncology Fellowship program.
- Clinical Expertise: Hematology; Disorders of Hemostasis and Thrombosis
- Languages Spoken: English
- Education: MBBS, Byramjee Jeejeebhoy Medical College (India)
- Residencies: Rush-Presbyterian-St.Luke's Medical Center (Illinois)
- Fellowships: Indiana University Medical Center
- Board Certifications: Internal Medicine; Hematology; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.